LENZ Therapeutics Inc

LENZ is in a Stage 4 decline with persistent lower highs and lower lows under down-sloping EMAs, confirming bearish structure across both medium and long terms. Short-term execution timing is neutral as price tightly tracks below declining EMAs amid extreme oversold readings, offering no clear entry. With a speculative strategy requiring high selectivity, execution is deferred and best considered on any rally into EMA resistance.

• ↑Moderate Buy consensus with $28.80 price target implies ~509% upside.
• ↑VIZZ prescriptions surged 45% month-over-month after marketing push.
• ↓Q2 2026 net loss of $31.9M despite VIZZ revenue growth.